arrow
A

Antonella Ravaggi

Angelo Nocivelli Institute of Molecular Medicine
H指数:45
被引数:5,756

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Response to Correspondence of Cheng W. et al. on “Decoding BRCA1 and BRCA2 mutations in high-grade serous ovarian cancer: impact of location and type of mutation on prognosis and PARP inhibitor treatment” by Momi M. et al.

对Cheng W.等人在“Decoding BRCA1 and BRCA2 mutations in high-grade serous ovarian cancer: impact of location and type of mutation on prognosis and PARP inhibitor treatment”一文中关于Momi M.等人通讯的回复

2026-07-120
PRE
Decoding BRCA1 and BRCA2 mutations in high-grade serous ovarian cancer: impact of location and type of mutation on prognosis and PARP inhibitor treatment

解码高级别浆液性卵巢癌中的BRCA1和BRCA2突变:突变位置和类型对预后及PARP抑制剂治疗的影响

2026-04-030
PRE
Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix
2024-04-161
PRE
PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine

使用反相蛋白质微阵列对肿瘤类型进行PD-L1定量: 对精准医学的影响

2021-10-077
OAAI
Immunotherapy for the prevention of high-risk oral disorders malignant transformation: the IMPEDE trial

预防高危口腔疾病恶性转化的免疫疗法: 阻碍试验

2021-05-177
OAAI
Integrated mutational landscape analysis of uterine leiomyosarcomas
2021-04-0568
OA
Low Expression of Claudin-7 as Potential Predictor of Distant Metastases in High-Grade Serous Ovarian Carcinoma Patients

Claudin-7低表达可作为高级别浆液性卵巢癌患者远处转移的潜在预测因子

2020-08-048
OAAI
Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer

PRKG1,SDF2L1和PPP1R12A的表达谱是高级别浆液性卵巢癌治疗反应和生存的预测和预后因素

2020-03-1316
OAAI